Literature DB >> 16474164

The level of reverse transcriptase (RT) in human immunodeficiency virus type 1 particles affects susceptibility to nonnucleoside RT inhibitors but not to lamivudine.

Zandrea Ambrose1, John G Julias, Paul L Boyer, Vineet N Kewalramani, Stephen H Hughes.   

Abstract

We investigated the relationship between the level of reverse transcriptase (RT) in human immunodeficiency virus type 1 (HIV-1) particles and susceptibility to nonnucleoside reverse transcriptase inhibitors (NNRTIs). HIV-1 virions containing different active levels of RT were generated. Susceptibility to the NNRTIs efavirenz and nevirapine was inversely proportional to the level of enzymatically active RT. However, the sensitivity of HIV-1 to the nucleoside analog 3TC was not affected by the level of RT per particle. These data indicate that the susceptibility of HIV-1 to NNRTIs is influenced by RT activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16474164      PMCID: PMC1395365          DOI: 10.1128/JVI.80.5.2578-2581.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  19 in total

1.  Replication of phenotypically mixed human immunodeficiency virus type 1 virions containing catalytically active and catalytically inactive reverse transcriptase.

Authors:  J G Julias; A L Ferris; P L Boyer; S H Hughes
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy.

Authors:  N Shulman; A R Zolopa; D Passaro; R W Shafer; W Huang; D Katzenstein; D M Israelski; N Hellmann; C Petropoulos; J Whitcomb
Journal:  AIDS       Date:  2001-06-15       Impact factor: 4.177

3.  Genetic correlates of efavirenz hypersusceptibility.

Authors:  Nancy S Shulman; Ronald J Bosch; John W Mellors; Mary A Albrecht; David A Katzenstein
Journal:  AIDS       Date:  2004-09-03       Impact factor: 4.177

4.  Analysis of HIV particle formation using transient expression of subviral constructs in mammalian cells.

Authors:  K Mergener; M Fäcke; R Welker; V Brinkmann; H R Gelderblom; H G Kräusslich
Journal:  Virology       Date:  1992-01       Impact factor: 3.616

5.  Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.

Authors:  Jeannette M Whitcomb; Wei Huang; Kay Limoli; Ellen Paxinos; Terri Wrin; Gail Skowron; Steven G Deeks; Michael Bates; Nicholas S Hellmann; Christos J Petropoulos
Journal:  AIDS       Date:  2002-10-18       Impact factor: 4.177

6.  The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis.

Authors:  Richard H Haubrich; Carol A Kemper; Nicholas S Hellmann; Philip H Keiser; Mallory D Witt; Donald N Forthal; John Leedom; Matthew Leibowitz; Jeannette M Whitcomb; Douglas Richman; J Allen McCutchan
Journal:  AIDS       Date:  2002-10-18       Impact factor: 4.177

7.  The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis.

Authors:  M Götte; D Arion; M A Parniak; M A Wainberg
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

8.  In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.

Authors:  Zandrea Ambrose; Valerie Boltz; Sarah Palmer; John M Coffin; Stephen H Hughes; Vineet N Kewalramani
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

9.  Relationships between infectious titer, capsid protein levels, and reverse transcriptase activities of diverse human immunodeficiency virus type 1 isolates.

Authors:  Andre J Marozsan; Erika Fraundorf; Awet Abraha; Heather Baird; Dawn Moore; Ryan Troyer; Immaculate Nankja; Eric J Arts
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

10.  Overexpression of the gag-pol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production.

Authors:  J Park; C D Morrow
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

View more
  10 in total

1.  Human immunodeficiency virus type 1 capsid mutation N74D alters cyclophilin A dependence and impairs macrophage infection.

Authors:  Zandrea Ambrose; KyeongEun Lee; Jean Ndjomou; Hongzhan Xu; Ilker Oztop; James Matous; Taichiro Takemura; Derya Unutmaz; Alan Engelman; Stephen H Hughes; Vineet N KewalRamani
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

2.  Drug effectiveness explained: the mathematics of antiviral agents for HIV.

Authors:  Alan S Perelson; Steven G Deeks
Journal:  Sci Transl Med       Date:  2011-07-13       Impact factor: 17.956

Review 3.  The choreography of HIV-1 proteolytic processing and virion assembly.

Authors:  Sook-Kyung Lee; Marc Potempa; Ronald Swanstrom
Journal:  J Biol Chem       Date:  2012-10-05       Impact factor: 5.157

4.  Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitor.

Authors:  Meiqing Lu; Peter J Felock; Vandna Munshi; Renee C Hrin; Ying-Jie Wang; Youwei Yan; Sanjeev Munshi; Georgia B McGaughey; Robert Gomez; Neville J Anthony; Theresa M Williams; Jay A Grobler; Daria J Hazuda; Philip M McKenna; Michael D Miller; Ming-Tain Lai
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

5.  Interplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivity.

Authors:  Gavin J Henderson; Sook-Kyung Lee; David M Irlbeck; Janera Harris; Melissa Kline; Elizabeth Pollom; Neil Parkin; Ronald Swanstrom
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

6.  Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.

Authors:  Ming-Tain Lai; Vandna Munshi; Sinoeun Touch; Robert M Tynebor; Thomas J Tucker; Philip M McKenna; Theresa M Williams; Daniel J DiStefano; Daria J Hazuda; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2009-03-16       Impact factor: 5.191

7.  In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.

Authors:  Ming-Tain Lai; Meizhen Feng; Jean-Pierre Falgueyret; Paul Tawa; Marc Witmer; Daniel DiStefano; Yuan Li; Jason Burch; Nancy Sachs; Meiqing Lu; Elizabeth Cauchon; Louis-Charles Campeau; Jay Grobler; Youwei Yan; Yves Ducharme; Bernard Côté; Ernest Asante-Appiah; Daria J Hazuda; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2013-12-30       Impact factor: 5.191

8.  A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs.

Authors:  Lin Shen; S Alireza Rabi; Ahmad R Sedaghat; Liang Shan; Jun Lai; Sifei Xing; Robert F Siliciano
Journal:  Sci Transl Med       Date:  2011-07-13       Impact factor: 17.956

9.  Two Coselected Distal Mutations in HIV-1 Reverse Transcriptase (RT) Alter Susceptibility to Nonnucleoside RT Inhibitors and Nucleoside Analogs.

Authors:  Paul L Boyer; Kevin Melody; Steven J Smith; Linda L Dunn; Chris Kline; Douglas K Fischer; Richa Dwivedi; Pat Clark; Stephen H Hughes; Zandrea Ambrose
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

10.  Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs.

Authors:  Lin Shen; Susan Peterson; Ahmad R Sedaghat; Moira A McMahon; Marc Callender; Haili Zhang; Yan Zhou; Eleanor Pitt; Karen S Anderson; Edward P Acosta; Robert F Siliciano
Journal:  Nat Med       Date:  2008-06-15       Impact factor: 53.440

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.